Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 7203587, 18 pages
http://dx.doi.org/10.1155/2016/7203587
Review Article

Hib Vaccines: Past, Present, and Future Perspectives

1Biological Sciences Department, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia
2Main Medical Laboratory, Medical Services, Saudi Airlines, P.O. Box 167, Cost Center 507, Jeddah 21231, Saudi Arabia
3Therapeutic and Protective Proteins Laboratory, Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City for Scientific Research and Technology Applications, New Borg EL-Arab, Alexandria 21934, Egypt

Received 31 October 2015; Accepted 24 December 2015

Academic Editor: Clelia M. Riera

Copyright © 2016 Adi Essam Zarei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. E. Adderson, C. L. Byington, L. Spencer et al., “Invasive serotype a Haemophilus influenzae infections with a virulence genotype resembling Haemophilus influenzae type b: emerging pathogen in the vaccine era?” Pediatrics, vol. 108, no. 1, article E18, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. M. G. Bruce, S. L. Deeks, T. Zulz et al., “Epidemiology of Haemophilus influenzae serotype a, North American Arctic, 2000–2005,” Emerging Infectious Diseases, vol. 14, no. 1, pp. 48–55, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. C. Parke Jr., R. Schneerson, and J. B. Robbins, “The attack rate, age incidence, racial distribution, and case fatality rate of Hemophilus influenzae type b meningitis in Mecklenburg County, North Carolina,” The Journal of Pediatrics, vol. 81, no. 4, pp. 765–769, 1972. View at Publisher · View at Google Scholar · View at Scopus
  4. J. N. Hanna, “The epidemiology of invasive Haemophilus influenzae infections in children under five years of age in the Northern Territory: a three-year study,” Medical Journal of Australia, vol. 152, no. 5, pp. 234–240, 1990. View at Google Scholar · View at Scopus
  5. J. I. Ward, H. S. Margolis, M. K. Lum, D. W. Fraser, T. R. Bender, and P. Anderson, “Haemophilus influenzae disease in Alaskan Eskimos: characteristics of a population with an unusual incidence of invasive disease,” The Lancet, vol. 1, no. 8233, pp. 1281–1285, 1981. View at Google Scholar
  6. S. H. Sell, R. E. Merrill, E. O. Doyne, and E. P. Zimsky Jr., “Long-term sequelae of Hemophilus influenzae meningitis,” Pediatrics, vol. 49, no. 2, pp. 206–211, 1972. View at Google Scholar · View at Scopus
  7. M. Glode, R. S. Daum, D. A. Goldmann, J. Leclair, and A. Smith, “Haemophilus influenzae type B meningitis: a contagious disease of children,” The British Medical Journal, vol. 280, no. 6218, pp. 899–901, 1980. View at Publisher · View at Google Scholar · View at Scopus
  8. M. P. Glode, M. S. Schiffer, J. B. Robbins, W. Khan, U. Battle, and E. Armenta, “An outbreak of Hemophilus influenzae type b meningitis in an enclosed hospital population,” The Journal of Pediatrics, vol. 88, no. 1, pp. 36–40, 1976. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Claesson, B. Trollfors, B. Ekstrom-Jodal et al., “Incidence and prognosis of acute epiglottitis in children in a Swedish region,” Pediatric Infectious Disease, vol. 3, no. 6, pp. 534–538, 1984. View at Publisher · View at Google Scholar · View at Scopus
  10. G. J. Nabel, “Designing tomorrow's vaccines,” The New England Journal of Medicine, vol. 368, no. 6, pp. 551–560, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Y. Avci, “Novel strategies for development of next-generation glycoconjugate vaccines,” Current Topics in Medicinal Chemistry, vol. 13, no. 20, pp. 2535–2540, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Kuberan and R. J. Linhardt, “Carbohydrate based vaccines,” Current Organic Chemistry, vol. 4, no. 6, pp. 653–677, 2000. View at Google Scholar
  13. P. T. Heath, “Haemophilus influenzae type b conjugate vaccines: a review of efficacy data,” Pediatric Infectious Disease Journal, vol. 17, no. 9, pp. S117–S122, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Zandvoort and W. Timens, “The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens,” Clinical and Experimental Immunology, vol. 130, no. 1, pp. 4–11, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Nieminen, H. Käyhty, A. Virolainen, and J. Eskola, “Circulating antibody secreting cell response to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody response,” Vaccine, vol. 16, no. 2-3, pp. 313–319, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. Q. Zhang, S. Choo, J. Everard, R. Jennings, and A. Finn, “Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents,” Infection and Immunity, vol. 68, no. 5, pp. 2692–2697, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. Q. Vos, A. Lees, Z.-Q. Wu, C. M. Snapper, and J. J. Mond, “B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms,” Immunological Reviews, vol. 176, pp. 154–170, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. D. M. Musher, J. E. Groover, D. A. Watson et al., “Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides,” Journal of Investigative Medicine, vol. 45, no. 2, pp. 57–68, 1997. View at Google Scholar · View at Scopus
  19. D. M. Granoff, R. K. Gupta, R. B. Belshe, and E. L. Andersen, “Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination,” Journal of Infectious Diseases, vol. 178, no. 3, pp. 870–874, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. C. B. Wilson, D. B. Lewis, and L. A. Penix, “The physiologic immunodeficiency of immaturity,” in Immunologic Disorders in Infants and Children, E. R. Stiehm, Ed., pp. 253–295, W.B. Saunders, Philadelphia, Pa, USA, 4th edition, 1996. View at Google Scholar
  21. C. Laferriere, “The immunogenicity of pneumococcal polysaccharides in infants and children: a meta-regression,” Vaccine, vol. 29, no. 40, pp. 6838–6847, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. W. S. Pomat, D. Lehmann, R. C. Sanders et al., “Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea,” Infection and Immunity, vol. 62, no. 5, pp. 1848–1853, 1994. View at Google Scholar · View at Scopus
  23. B. P. Arulanandam, J. N. Mittler, W. T. Lee, M. O'Toole, and D. W. Metzger, “Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines,” The Journal of Immunology, vol. 164, no. 7, pp. 3698–3704, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. M. O. C. Ota, J. Vekemans, S. E. Schlegel-Haueter et al., “Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults,” Vaccine, vol. 22, no. 3-4, pp. 511–519, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Rowe, C. Macaubas, T. Monger et al., “Heterogeneity in diphtheria-tetanus-acellular pertussis vaccine-specific cellular immunity during infancy: relationship to variations in the kinetics of postnatal maturation of systemic Th1 function,” Journal of Infectious Diseases, vol. 184, no. 1, pp. 80–88, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Vekemans, M. O. C. Ota, E. C. Y. Wang et al., “T cell responses to vaccines in infants: defective IFNγ production after oral polio vaccination,” Clinical and Experimental Immunology, vol. 127, no. 3, pp. 495–498, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. O. J. White, K. L. McKenna, A. Bosco, A. H. J. van den Biggelaar, P. Richmond, and P. G. Holt, “A genomics-based approach to assessment of vaccine safety and immunogenicity in children,” Vaccine, vol. 30, no. 10, pp. 1865–1874, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. O. J. White, J. Rowe, P. Richmond et al., “Th2-polarisation of cellular immune memory to neonatal pertussis vaccination,” Vaccine, vol. 28, no. 14, pp. 2648–2652, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. C.-A. Siegrist, “Neonatal and early life vaccinology,” Vaccine, vol. 19, no. 25-26, pp. 3331–3346, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Finn, “Bacterial polysaccharide-protein conjugate vaccines,” British Medical Bulletin, vol. 70, pp. 1–14, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Swingler, D. Fransman, and G. Hussey, “Conjugate vaccines for preventing Haemophilus influenzae type b infections,” Cochrane Database of Systematic Reviews, vol. 4, Article ID CD001729, 2003. View at Google Scholar
  32. P. T. Heath, R. Booy, H. Griffiths et al., “Clinical and immunological risk factors associated with haemophilus influenzae type b conjugate vaccine failure in childhood,” Clinical Infectious Diseases, vol. 31, no. 4, pp. 973–980, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. S. R. Dominguez and R. S. Daum, “Toward global Haemophilus influenzae type b immunization,” Clinical Infectious Diseases, vol. 37, no. 12, pp. 1600–1602, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. R. T. Mahoney and J. E. Maynard, “The introduction of new vaccines into developing countries,” Vaccine, vol. 17, no. 7-8, pp. 646–652, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Arvas, E. Gur, H. Bahar et al., “Haemophilus influenzae type b antibodies in vaccinated and non-vaccinated children,” Pediatrics International, vol. 50, no. 4, pp. 469–473, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Almuneef, M. Alshaalan, Z. Memish, and S. Alalola, “Bacterial meningitis in Saudi Arabia: the impact of Haemophilus influenzae type b vaccination,” Journal of Chemotherapy, vol. 13, supplement 1, pp. 34–39, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. F. A. Al-Zamil, “Conjugated pneumococcal vaccine for children in Saudi Arabia: following the footsteps of hib vaccine,” The Journal of the Egyptian Public Health Association, vol. 83, no. 1-2, pp. 35–47, 2008. View at Google Scholar
  38. Health Statistic Annual Book: Kingdom of Saudi Arabia Ministry of Health, 2013, http://www.moh.gov.sa/en/Ministry/Statistics/book/Documents/Statistics-Book-1434.pdf.
  39. Global Programme for Vaccines and Immunization (GPV), “The WHO position paper on Haemophilus influenzae type b conjugate vaccines,” The Weekly Epidemiological Record, vol. 73, no. 10, pp. 64–68, 1998. View at Google Scholar
  40. M. Finland and W. D. Sutliff, “Specific antibody response of human subjects to intracutaneous injection of pneumococcus products,” The Journal of Experimental Medicine, vol. 55, no. 6, pp. 853–865, 1932. View at Publisher · View at Google Scholar
  41. C. L. Hoagland, P. B. Beeson, and W. F. Goebel, “The capsular polysaccharide of the type XIV pneumococcus and its relationship to the specific substances of human blood,” Science, vol. 88, no. 2281, pp. 261–263, 1938. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Kayhty, V. Karanko, H. Peltola, and P. H. Makela, “Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory,” Pediatrics, vol. 74, no. 5, pp. 857–865, 1984. View at Google Scholar · View at Scopus
  43. J. B. Robbins and R. Schneerson, “Polysaccharide-protein conjugates: a new generation of vaccines,” The Journal of Infectious Diseases, vol. 161, no. 5, pp. 821–832, 1990. View at Publisher · View at Google Scholar · View at Scopus
  44. J. I. Ward, C. V. Broome, L. H. Harrison, H. Shinefield, and S. Black, “Haemophilus influenzae type b vaccines: lessons for the future,” Pediatrics, vol. 81, no. 6, pp. 886–893, 1988. View at Google Scholar · View at Scopus
  45. H. Kayhty, H. Peltola, V. Karanko, and P. H. Makela, “The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b,” Journal of Infectious Diseases, vol. 147, no. 6, p. 1100, 1983. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Z. Dintzis, M. Okajima, M. H. Middleton, G. Greene, and H. M. Dintzis, “The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence,” The Journal of Immunology, vol. 143, no. 4, pp. 1239–1244, 1989. View at Google Scholar · View at Scopus
  47. J. C. Aguilar and E. G. Rodríguez, “Vaccine adjuvants revisited,” Vaccine, vol. 25, no. 19, pp. 3752–3762, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. B. Guy, “Adjuvants for protein- and carbohydrate-based vaccines,” in Carbohydrate-Based Vaccines and Immunotherapies, pp. 89–115, John Wiley & Sons, New York, NY, USA, 2008. View at Google Scholar
  49. T. A. Barr, J. Carlring, and A. W. Heath, “Co-stimulatory agonists as immunological adjuvants,” Vaccine, vol. 24, no. 17, pp. 3399–3407, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. E. C. Briere, L. Rubin, P. L. Moro, A. Cohn, T. Clark, and N. Messonnier, “Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP),” Morbidity and Mortality Weekly Report, vol. 63, no. 1, pp. 1–14, 2014. View at Google Scholar
  51. R. Z. Dintzis, “Rational design of conjugate vaccines,” Pediatric Research, vol. 32, no. 4, pp. 376–385, 1992. View at Publisher · View at Google Scholar · View at Scopus
  52. K. E. Stein, “Glycoconjugate vaccines. What next?” International Journal of Technology Assessment in Health Care, vol. 10, no. 1, pp. 167–176, 1994. View at Publisher · View at Google Scholar · View at Scopus
  53. A. A. Lindberg, “Glycoprotein conjugate vaccines,” Vaccine, vol. 17, supplement 2, pp. S28–S36, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. J. L. Hsu, “A brief history of vaccines: smallpox to the present,” South Dakota Medicine, Special no. 33–37, 2013. View at Google Scholar
  55. S. A. Plotkin and S. L. Plotkin, “The development of vaccines: how the past led to the future,” Nature Reviews Microbiology, vol. 9, no. 12, pp. 889–893, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. A. H. J. van den Biggelaar and W. S. Pomat, “Immunization of newborns with bacterial conjugate vaccines,” Vaccine, vol. 31, no. 21, pp. 2525–2530, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. W. E. Dick Jr. and M. Beurret, “Glycoconjugates of bacterial carbohydrate antigens. A survey and consideration of design and preparation factors,” Contributions to Microbiology and Immunology, vol. 10, pp. 48–114, 1989. View at Google Scholar · View at Scopus
  58. A. Lees, V. Puvanesarajah, and C. E. Frasch, “Conjugation chemistry,” in Pneumococcal Vaccines, pp. 163–174, American Society of Microbiology, 2008. View at Google Scholar
  59. W. Zou and H. J. Jennings, “Preparation of glycoconjugate vaccines,” in Carbohydrate-Based Vaccines and Immunotherapies, Z. Guo and G.-J. Boons, Eds., John Wiley & Sons, New York, NY, USA, 2009. View at Publisher · View at Google Scholar
  60. G. Toraño, M. E. Toledo, A. Baly et al., “Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b in human adult volunteers,” Clinical and Vaccine Immunology, vol. 13, no. 9, pp. 1052–1056, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Bay, V. Huteau, M.-L. Zarantonelli et al., “Phosphorylcholine-carbohydrate-protein conjugates efficiently induce hapten-specific antibodies which recognize both Streptococcus pneumoniae and Neisseria meningitidis: a potential multitarget vaccine against respiratory infections,” Journal of Medicinal Chemistry, vol. 47, no. 16, pp. 3916–3919, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. T. Buskas, Y. Li, and G. J. Boons, “The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein,” Chemistry, vol. 10, no. 14, pp. 3517–3524, 2004. View at Publisher · View at Google Scholar
  63. P. H. Seeberger, R. L. Soucy, Y.-U. Kwon, D. A. Snyder, and T. Kanemitsu, “A convergent, versatile route to two synthetic conjugate anti-toxin malaria vaccines,” Chemical Communications, vol. 10, no. 15, pp. 1706–1707, 2004. View at Google Scholar · View at Scopus
  64. V. Verez-Bencomo, V. Fernández-Santana, E. Hardy et al., “A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b,” Science, vol. 305, no. 5683, pp. 522–525, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. C. C. A. M. Peeters, A.-M. J. Tenbergen-Meekes, J. T. Poolman, B. J. M. Zegers, and G. T. Rijkers, “Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide-protein conjugate vaccine is decreased by admixture of high doses of free saccharide,” Vaccine, vol. 10, no. 12, pp. 833–840, 1992. View at Publisher · View at Google Scholar · View at Scopus
  66. M. E. Rodriguez, G. P. J. M. van den Dobbelsteen, L. A. Oomen et al., “Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response,” Vaccine, vol. 16, no. 20, pp. 1941–1949, 1998. View at Publisher · View at Google Scholar · View at Scopus
  67. G. R. Gray, “Antibodies to carbohydrates: preparation of antigens by coupling carbohydrates to proteins by reductive amination with cyanoborohydride,” Methods in Enzymology, vol. 50, pp. 155–160, 1978. View at Publisher · View at Google Scholar
  68. B. A. Schwartz and G. R. Gray, “Proteins containing reductively aminated disaccharides. Synthesis and chemical characterization,” Archives of Biochemistry and Biophysics, vol. 181, no. 2, pp. 542–549, 1977. View at Publisher · View at Google Scholar · View at Scopus
  69. M. L. C. Da Silva, T. Tamura, T. McBroom, and K. G. Rice, “Tyrosine derivatization and preparative purification of the sialyl and asialyl N-linked oligosaccharides from porcine fibrinogen,” Archives of Biochemistry and Biophysics, vol. 312, no. 1, pp. 151–157, 1994. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Y. C. Wong, G. R. Guile, R. A. Dwek, and G. Arsequell, “Synthetic glycosylation of proteins using N-(β-saccharide) iodoacetamides: applications in site-specific glycosylation and solid-phase enzymic oligosaccharide synthesis,” Biochemical Journal, vol. 300, no. 3, pp. 843–850, 1994. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Y. C. Wong, G. R. Guile, T. W. Rademacher, and R. A. Dwek, “Synthetic glycosylation of peptides using unprotected saccharide beta-glycosylamines,” Glycoconjugate Journal, vol. 10, no. 3, pp. 227–234, 1993. View at Google Scholar · View at Scopus
  72. G. Ragupathi, R. R. Koganty, D. Qiu, K. O. Lloyd, and P. O. Livingston, “A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm,” Glycoconjugate Journal, vol. 15, no. 3, pp. 217–221, 1998. View at Publisher · View at Google Scholar · View at Scopus
  73. E. C. Beuvery, G. J. Speijers, B. I. Lutz et al., “Analytical, toxicological and immunological consequences of the use of N-ethyl-N′-(3-dimethylaminopropyl) carbodiimide as coupling reagent for the preparation of meningococcal group C polysaccharide-tetanus toxoid conjugate as vaccine for human use,” Developments in Biological Standardization, vol. 63, pp. 117–128, 1986. View at Google Scholar
  74. J. V. Staros, R. W. Wright, and D. M. Swingle, “Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions,” Analytical Biochemistry, vol. 156, no. 1, pp. 220–222, 1986. View at Publisher · View at Google Scholar · View at Scopus
  75. O. T. Avery and W. F. Goebel, “Chemo-immunological studies on conjugated carbohydrate-proteins: V. The immunological specifity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein,” The Journal of Experimental Medicine, vol. 54, no. 3, pp. 437–447, 1931. View at Publisher · View at Google Scholar
  76. R. Axén, J. Porath, and S. Ernback, “Chemical coupling of peptides and proteins to polysaccharides by means of cyanogen halides,” Nature, vol. 214, no. 5095, pp. 1302–1304, 1967. View at Publisher · View at Google Scholar · View at Scopus
  77. L. Chi-Jen, “Bacterial capsular polysaccharides—biochemistry, immunity and vaccine,” Molecular Immunology, vol. 24, no. 10, pp. 1005–1019, 1987. View at Publisher · View at Google Scholar · View at Scopus
  78. L. C. Paoletti, M. A. Rench, D. L. Kasper, D. Molrine, D. Ambrosino, and C. J. Baker, “Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines,” Infection and Immunity, vol. 69, no. 11, pp. 6696–6701, 2001. View at Publisher · View at Google Scholar
  79. A. W. Sturgess, K. Rush, R. J. Charbonneau et al., “Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide,” Vaccine, vol. 17, no. 9-10, pp. 1169–1178, 1999. View at Publisher · View at Google Scholar · View at Scopus
  80. R. S. Chu, T. McCool, N. S. Greenspan, J. R. Schreiber, and C. V. Harding, “CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies,” Infection and Immunity, vol. 68, no. 3, pp. 1450–1456, 2000. View at Publisher · View at Google Scholar · View at Scopus
  81. T. A. Olafsdottir, S. G. Hannesdottir, G. D. Giudice, E. Trannoy, and I. Jonsdottir, “Effects of LT-K63 and CpG2006 on phenotype and function of murine neonatal lymphoid cells,” Scandinavian Journal of Immunology, vol. 66, no. 4, pp. 426–434, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. G. Sen, Q. Chen, and C. M. Snapper, “Immunization of aged mice with a pneumococcal conjugate vaccine combined with an unmethylated CpG-containing oligodeoxynucleotide restores defective immunoglobulin G antipolysaccharide responses and specific CD4+-T-cell priming to young adult levels,” Infection and Immunity, vol. 74, no. 4, pp. 2177–2186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. T. Barington, M. Skettrup, L. Juul, and C. Heilmann, “Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components,” Infection and Immunity, vol. 61, no. 2, pp. 432–438, 1993. View at Google Scholar · View at Scopus
  84. A. Fattom, Y. H. Cho, C. Chu, S. Fuller, L. Fries, and R. Naso, “Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines,” Vaccine, vol. 17, no. 2, pp. 126–133, 1999. View at Publisher · View at Google Scholar · View at Scopus
  85. M.-P. Schutze, E. Deriaud, G. Przewlocki, and C. LeClerc, “Carrier-induced epitopic suppression is initiated through clonal dominance,” The Journal of Immunology, vol. 142, no. 8, pp. 2635–2640, 1989. View at Google Scholar · View at Scopus
  86. Organization WHO, “Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines,” WHO Technical Report Series, no. 897, pp. 27–60, 2000. View at Google Scholar
  87. World Health Organization, “WHO position paper on Haemophilus influenzae type b conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record,” The Weekly Epidemiological Record, vol. 81, no. 47, pp. 445–452, 2006. View at Google Scholar
  88. “Progress introducing Haemophilus influenzae type b vaccine in low-income countries, 2004–2008,” Weekly Epidemiological Record, vol. 83, no. 7, pp. 61–67, 2008.
  89. B. D. Gessner, A. Sutanto, M. Linehan et al., “Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial,” The Lancet, vol. 365, no. 9453, pp. 43–52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. H. Peltola, “Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates,” Clinical Microbiology Reviews, vol. 13, no. 2, pp. 302–317, 2000. View at Publisher · View at Google Scholar · View at Scopus
  91. O. S. Levine, B. Schwartz, N. Pierce, and M. Kane, “Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: current status and priority actions,” The Pediatric Infectious Disease Journal, vol. 17, no. 9, supplement, pp. S95–S113, 1998. View at Publisher · View at Google Scholar · View at Scopus
  92. Lessons learned: new procurement strategies for vaccines. Final report to the GAVI board, GAVI Alliance: Mercer Management Consulting, 2002, http://www.gavi.org/library/gavi-documents/supply-procurement/mercer-report-on-vaccine-procurement.
  93. M. C. Danovaro-Holliday, S. Garcia, C. de Quadros, G. Tambini, and J. K. Andrus, “Progress in vaccination against Haemophilus influenzae type b in the Americas,” PLoS Medicine, vol. 5, no. 4, article e87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Landaverde, J. L. Di Fabio, G. Ruocco, I. Leal, and C. de Quadros, “Introduction of a conjugate vaccine against Hib in Chile and Uruguay,” Revista Panamericana de Salud Pública, vol. 5, no. 3, pp. 200–206, 1999. View at Publisher · View at Google Scholar
  95. J. D. Wenger, J.-L. DiFabio, J. M. Landaverde, O. S. Levine, and T. Gaafar, “Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four ‘newly adopting’ countries,” Vaccine, vol. 18, no. 7-8, pp. 736–742, 1999. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Hamidi, C. Boog, S. Jadhav, and H. Kreeftenberg, “Lessons learned during the development and transfer of technology related to a new Hib conjugate vaccine to emerging vaccine manufacturers,” Vaccine, vol. 32, no. 33, pp. 4124–4130, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. J. B. Milstien, P. Gaulé, and M. Kaddar, “Access to vaccine technologies in developing countries: Brazil and India,” Vaccine, vol. 25, no. 44, pp. 7610–7619, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Beurret, A. Hamidi, and H. Kreeftenberg, “Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries,” Vaccine, vol. 30, no. 33, pp. 4897–4906, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. F. Mawas, G. Newman, S. Burns, and M. J. Corbel, “Suppression and modulation of cellular and humoral immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine in Hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: a study in a rat model,” Journal of Infectious Diseases, vol. 191, no. 1, pp. 58–64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. Arabio Company, 2006, http://www.arabio.com/index.html.
  101. S. A. Plotkin, “Vaccines: the fourth century,” Clinical and Vaccine Immunology, vol. 16, no. 12, pp. 1709–1719, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. G. M. Glenn, D. N. Taylor, X. Li, S. Frankel, A. Montemarano, and C. R. Alving, “Transcutaneous immunization: a human vaccine delivery strategy using a patch,” Nature Medicine, vol. 6, no. 12, pp. 1403–1406, 2000. View at Publisher · View at Google Scholar · View at Scopus
  103. A.-S. Beignon, J.-P. Briand, S. Muller, and C. D. Partidos, “Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge,” Immunology, vol. 102, no. 3, pp. 344–351, 2001. View at Publisher · View at Google Scholar · View at Scopus
  104. A.-S. Beignon, J.-P. Briand, R. Rappuoli, S. Muller, and C. D. Partidos, “The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4+ T cells and secrete gamma interferon after coapplication onto bare skin,” Infection and Immunity, vol. 70, no. 6, pp. 3012–3019, 2002. View at Publisher · View at Google Scholar · View at Scopus
  105. G. M. Glenn, T. Scharton-Kersten, R. Vassell, C. P. Mallett, T. L. Hale, and C. R. Alving, “Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge,” The Journal of Immunology, vol. 161, no. 7, pp. 3211–3214, 1998. View at Google Scholar · View at Scopus
  106. C. M. Gockel, S. Bao, and K. W. Beagley, “Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract,” Molecular Immunology, vol. 37, no. 9, pp. 537–544, 2000. View at Publisher · View at Google Scholar · View at Scopus
  107. S. Godefroy, L. Goestch, H. Plotnicky-Gilquin et al., “Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against Respiratory Syncytial Virus (RSV),” Vaccine, vol. 21, no. 15, pp. 1665–1671, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. R. Tierney, A.-S. Beignon, R. Rappuoli, S. Muller, D. Sesardic, and C. Partidos, “Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses,” Journal of Infectious Diseases, vol. 188, no. 5, pp. 753–758, 2003. View at Publisher · View at Google Scholar · View at Scopus
  109. B. Quiambao, O. Van Der Meeren, D. Kolhe, and S. Gatchalian, “A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers,” Human Vaccines & Immunotherapeutics, vol. 8, no. 3, pp. 347–354, 2012. View at Publisher · View at Google Scholar · View at Scopus
  110. H. Kalies, V. Grote, T. Verstraeten, L. Hessel, H.-J. Schmitt, and R. Von Kries, “The use of combination vaccines has improved timeliness of vaccination in children,” Pediatric Infectious Disease Journal, vol. 25, no. 6, pp. 507–512, 2006. View at Publisher · View at Google Scholar · View at Scopus
  111. L. E. Happe, O. E. Lunacsek, D. T. Kruzikas, and G. S. Marshall, “Impact of a pentavalent combination vaccine on immunization timeliness in a state medicaid population,” Pediatric Infectious Disease Journal, vol. 28, no. 2, pp. 98–101, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. V. Baldo, P. Bonanni, M. Castro et al., “Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b vaccine; Infanrix hexa: twelve years of experience in Italy,” Human Vaccines and Immunotherapeutics, vol. 10, no. 1, pp. 129–137, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. H. Kalies, V. Grote, A. Siedler, B. Gröndahl, H.-J. Schmitt, and R. von Kries, “Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany's experience after 5 years of licensure,” Vaccine, vol. 26, no. 20, pp. 2545–2552, 2008. View at Publisher · View at Google Scholar · View at Scopus
  114. H. O. Hallander, T. Lepp, M. Ljungman, E. Netterlid, and M. Andersson, “Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease,” APMIS, vol. 118, no. 11, pp. 878–887, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. M. S. Amstey, R. Insel, J. Munoz, and M. Pichichero, “Fetal-neonatal passive immunization against Hemophilus influenzae, type b,” American Journal of Obstetrics and Gynecology, vol. 153, no. 6, pp. 607–611, 1985. View at Publisher · View at Google Scholar · View at Scopus
  116. J. A. Englund, W. P. Glezen, C. Turner, J. Harvey, C. Thompson, and G. R. Siber, “Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines,” Journal of Infectious Diseases, vol. 171, no. 1, pp. 99–105, 1995. View at Publisher · View at Google Scholar · View at Scopus
  117. M. S. Einhorn, D. M. Granoff, M. H. Nahm, A. Quinn, and P. G. Shackelford, “Concentrations of antibodies in paired maternal and infant sera: relationship to IgG subclass,” The Journal of Pediatrics, vol. 111, no. 5, pp. 783–788, 1987. View at Publisher · View at Google Scholar · View at Scopus
  118. M. K. Park, J. A. Englund, W. P. Glezen, G. R. Siber, and M. H. Nahm, “Association of placental transfer of anti-Haemophilus influenzae type b polysaccharide antibodies with their V regions,” Vaccine, vol. 14, no. 13, pp. 1219–1222, 1996. View at Publisher · View at Google Scholar · View at Scopus
  119. A. M. Krieg, “Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA,” Trends in Microbiology, vol. 4, no. 2, pp. 73–77, 1996. View at Publisher · View at Google Scholar · View at Scopus
  120. V. E. Schijns, “Immunological concepts of vaccine adjuvant activity,” Current Opinion in Immunology, vol. 12, no. 4, pp. 456–463, 2000. View at Publisher · View at Google Scholar · View at Scopus
  121. C. A. Janeway Jr. and R. Medzhitov, “Introduction: the role of innate immunity in the adaptive immune response,” Seminars in Immunology, vol. 10, no. 5, pp. 349–350, 1998. View at Publisher · View at Google Scholar · View at Scopus
  122. M. Roman, E. Martin-Orozco, J. S. Goodman et al., “Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants,” Nature Medicine, vol. 3, no. 8, pp. 849–854, 1997. View at Publisher · View at Google Scholar · View at Scopus
  123. N. S. Greenspan and L. J. N. Cooper, “Intermolecular cooperativity: a clue to why mice have IgG3?” Immunology Today, vol. 13, no. 5, pp. 164–168, 1992. View at Publisher · View at Google Scholar · View at Scopus
  124. F. D. Finkelman, J. Holmes, I. M. Katona et al., “Lymphokine control of in vivo immunoglobulin isotype selection,” Annual Review of Immunology, vol. 8, pp. 303–333, 1990. View at Publisher · View at Google Scholar · View at Scopus
  125. A. R. Foxwell, J. M. Kyd, and A. W. Cripps, “Nontypeable Haemophilus influenzae: pathogenesis and prevention,” Microbiology and Molecular Biology Reviews, vol. 62, no. 2, pp. 294–308, 1998. View at Google Scholar · View at Scopus
  126. M. R. Loeb and D. H. Smith, “Outer membrane protein composition in disease isolates of Haemophilus influenzae: pathogenic and epidemiological implications,” Infection and Immunity, vol. 30, no. 3, pp. 709–717, 1980. View at Google Scholar · View at Scopus
  127. S. J. Barenkamp, R. S. Munson Jr., and D. M. Granoff, “Subtyping isolates of Haemophilus influenzae type b by outer-membrane protein profiles,” The Journal of Infectious Diseases, vol. 143, no. 5, pp. 668–676, 1981. View at Publisher · View at Google Scholar · View at Scopus
  128. M. Comanducci, S. Bambini, B. Brunelli et al., “NadA, a novel vaccine candidate of Neisseria meningitidis,” Journal of Experimental Medicine, vol. 195, no. 11, pp. 1445–1454, 2002. View at Publisher · View at Google Scholar · View at Scopus
  129. C. A. Janeway, P. Travers, M. Walport, and M. Chlomchik, Immunobiology, Garland Science Publishing, New York, NY, USA, 6th edition, 2005.
  130. N. A. Mitchison, “T-cell-B-cell cooperation,” Nature Reviews Immunology, vol. 4, no. 4, pp. 308–312, 2004. View at Publisher · View at Google Scholar
  131. F. Y. Avci and D. L. Kasper, “How bacterial carbohydrates influence the adaptive immune system,” Annual Review of Immunology, vol. 28, pp. 107–130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. B. A. Cobb, Q. Wang, A. O. Tzianabos, and D. L. Kasper, “Polysaccharide processing and presentation by the MHCII pathway,” Cell, vol. 117, no. 5, pp. 677–687, 2004. View at Publisher · View at Google Scholar · View at Scopus
  133. Á. G. Barrientos, J. M. de la Fuente, T. C. Rojas, A. Fernández, and S. Penadés, “Gold glyconanoparticles: synthetic polyvalent ligands mimicking glycocalyx-like surfaces as tools for glycobiological studies,” Chemistry—A European Journal, vol. 9, no. 9, pp. 1909–1921, 2003. View at Publisher · View at Google Scholar · View at Scopus
  134. F. Y. Avci, X. Li, M. Tsuji, and D. L. Kasper, “A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design,” Nature Medicine, vol. 17, no. 12, pp. 1602–1609, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. H. Amir-Kroll, L. Riveron, M. E. Sarmiento, G. Sierra, A. Acosta, and I. R. Cohen, “A conjugate vaccine composed of a heat shock protein 60 T-cell epitope peptide (p458) and Neisseria meningitidis type B capsular polysaccharide,” Vaccine, vol. 24, no. 42-43, pp. 6555–6563, 2006. View at Publisher · View at Google Scholar · View at Scopus
  136. N. Cohen, M. Stolarsky-Bennun, H. Amir-Kroll et al., “Pneumococcal capsular polysaccharide is immunogenic when present on the surface of macrophages and dendritic cells: TLR4 signaling induced by a conjugate vaccine or by lipopolysaccharide is conducive,” The Journal of Immunology, vol. 180, no. 4, pp. 2409–2418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  137. S. Könen-Waisman, A. Cohen, M. Fridkin, and I. R. Cohen, “Self heat-shock protein (hsp60) peptide serves in a conjugate vaccine against a lethal pneumococcal infection,” Journal of Infectious Diseases, vol. 179, no. 2, pp. 403–413, 1999. View at Publisher · View at Google Scholar · View at Scopus
  138. F. Falugi, R. Petracca, M. Mariani et al., “Rationally designed strings of promiscuous CD4+ T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines,” European Journal of Immunology, vol. 31, no. 12, pp. 3816–3824, 2001. View at Publisher · View at Google Scholar · View at Scopus
  139. K. Baraldo, E. Mori, A. Bartoloni et al., “Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein,” Infection and Immunity, vol. 73, no. 9, pp. 5835–5841, 2005. View at Publisher · View at Google Scholar · View at Scopus
  140. R. Rana, J. Dalal, D. Singh et al., “Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysaccharide chain lengths,” Vaccine, vol. 33, no. 23, pp. 2646–2654, 2015. View at Publisher · View at Google Scholar
  141. A. Bardotti, G. Averani, F. Berti et al., “Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases,” Vaccine, vol. 26, no. 18, pp. 2284–2296, 2008. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Bröker, P. M. Dull, R. Rappuoli, and P. Costantino, “Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages,” Vaccine, vol. 27, no. 41, pp. 5574–5580, 2009. View at Publisher · View at Google Scholar · View at Scopus
  143. P. Costantino, R. Rappuoli, and F. Berti, “The design of semi-synthetic and synthetic glycoconjugate vaccines,” Expert Opinion on Drug Discovery, vol. 6, no. 10, pp. 1045–1066, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. E. Altindis, “Antibacterial vaccine research in 21st century: from inoculation to genomics approaches,” Current Topics in Medicinal Chemistry, vol. 13, no. 20, pp. 2638–2646, 2013. View at Publisher · View at Google Scholar · View at Scopus
  145. M. N. Baeshen, A. M. Al-Hejin, R. S. Bora et al., “Production of biopharmaceuticals in E. coli: current scenario and future perspectives,” Journal of Microbiology and Biotechnology, vol. 25, no. 7, pp. 953–962, 2015. View at Publisher · View at Google Scholar
  146. N. A. Baeshen, M. N. Baeshen, A. Sheikh et al., “Cell factories for insulin production,” Microbial Cell Factories, vol. 13, article 141, 2014. View at Publisher · View at Google Scholar · View at Scopus
  147. N. A. El-Baky and E. M. Redwan, “Therapeutic alpha-interferons protein: structure, production, and biosimilar,” Preparative Biochemistry & Biotechnology, vol. 45, no. 2, pp. 109–127, 2015. View at Publisher · View at Google Scholar · View at Scopus
  148. N. A. El-Baky, V. N. Uversky, and E. M. Redwan, “Human consensus interferons: bridging the natural and artificial cytokines with intrinsic disorder,” Cytokine & Growth Factor Reviews, vol. 26, no. 6, pp. 637–645, 2015. View at Publisher · View at Google Scholar
  149. E.-R. M. Redwan, “Cumulative updating of approved biopharmaceuticals,” Human Antibodies, vol. 16, no. 3-4, pp. 137–158, 2007. View at Google Scholar · View at Scopus
  150. E.-R. M. Redwan, “Animal-derived pharmaceutical proteins,” Journal of Immunoassay and Immunochemistry, vol. 30, no. 3, pp. 262–290, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. Y. Liao, E. M. El-Fakkarany, B. Lönnerdal, and E. M. Redwan, “Inhibitory effects of native/recombinant full-length camel lactoferrin and its N/C lobes on hepatitis C virus infection of Huh7.5 cells,” Journal of Medical Microbiology, vol. 61, part 3, pp. 375–383, 2012. View at Publisher · View at Google Scholar
  152. E.-R. M. Redwan, A. Fahmy, A. E. Hanafy, N. A. EL-Baky, and S. M. A. Sallam, “Ovine anti-rabies antibody production and evaluation,” Comparative Immunology, Microbiology and Infectious Diseases, vol. 32, no. 1, pp. 9–19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  153. E.-R. M. Redwan, S. M. Matar, G. A. El-Aziz, and E. A. Serour, “Synthesis of the human insulin gene: protein expression, scaling up and bioactivity,” Preparative Biochemistry and Biotechnology, vol. 38, no. 1, pp. 24–39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  154. N. Jenkins, “Modifications of therapeutic proteins: challenges and prospects,” Cytotechnology, vol. 53, no. 1–3, pp. 121–125, 2007. View at Publisher · View at Google Scholar · View at Scopus
  155. G. Walsh and R. Jefferis, “Post-translational modifications in the context of therapeutic proteins,” Nature Biotechnology, vol. 24, no. 10, pp. 1241–1252, 2006. View at Publisher · View at Google Scholar · View at Scopus
  156. J. Ihssen, M. Kowarik, S. Dilettoso, C. Tanner, M. Wacker, and L. Thöny-Meyer, “Production of glycoprotein vaccines in Escherichia coli,” Microbial Cell Factories, vol. 9, article 61, 2010. View at Publisher · View at Google Scholar · View at Scopus
  157. M. Kowarik, S. Numao, M. F. Feldman et al., “N-linked glycosylation of folded proteins by the bacterial oligosaccharyltransferase,” Science, vol. 314, no. 5802, pp. 1148–1150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  158. V. S. Terra, D. C. Mills, L. E. Yates, S. Abouelhadid, J. Cuccui, and B. W. Wren, “Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design,” Journal of Medical Microbiology, vol. 61, no. 7, pp. 919–926, 2012. View at Publisher · View at Google Scholar · View at Scopus
  159. M. Wacker, D. Linton, P. G. Hitchen et al., “N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli,” Science, vol. 298, no. 5599, pp. 1790–1793, 2002. View at Publisher · View at Google Scholar · View at Scopus
  160. A. A. Ollis, S. Zhang, A. C. Fisher, and M. P. DeLisa, “Engineered oligosaccharyltransferases with greatly relaxed acceptor-site specificity,” Nature Chemical Biology, vol. 10, no. 10, pp. 816–822, 2014. View at Publisher · View at Google Scholar · View at Scopus
  161. J. D. Valderrama-Rincon, A. C. Fisher, J. H. Merritt et al., “An engineered eukaryotic protein glycosylation pathway in Escherichia coli,” Nature Chemical Biology, vol. 8, no. 5, pp. 434–436, 2012. View at Publisher · View at Google Scholar · View at Scopus
  162. J. Cuccui and B. Wren, “Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteins,” The Journal of Pharmacy and Pharmacology, vol. 67, no. 3, pp. 338–350, 2015. View at Publisher · View at Google Scholar
  163. J. H. Merritt, A. A. Ollis, A. C. Fisher, and M. P. Delisa, “Glycans-by-design: engineering bacteria for the biosynthesis of complex glycans and glycoconjugates,” Biotechnology and Bioengineering, vol. 110, no. 6, pp. 1550–1564, 2013. View at Publisher · View at Google Scholar · View at Scopus
  164. M. Wetter, M. Kowarik, M. Steffen, P. Carranza, G. Corradin, and M. Wacker, “Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component,” Glycoconjugate Journal, vol. 30, no. 5, pp. 511–522, 2013. View at Publisher · View at Google Scholar · View at Scopus
  165. A. C. Fisher, C. H. Haitjema, C. Guarino et al., “Production of secretory and extracellular N-linked glycoproteins in Escherichia coli,” Applied and Environmental Microbiology, vol. 77, no. 3, pp. 871–881, 2011. View at Publisher · View at Google Scholar · View at Scopus